Su, Yongwei <br/><br/>
Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.  [electronic resource] 

 -  Biochemical pharmacology  02 2018 
 - 13-26 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2968 
<br/><br/><label>Standard No.: </label>10.1016/j.bcp.2017.11.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Child<br/>Child, Preschool<br/>Drug Delivery Systems<br/>Extracellular Signal-Regulated MAP Kinases--genetics<br/>Female<br/>Gene Expression Regulation--drug effects<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Metabolic Networks and Pathways--drug effects<br/>Middle Aged<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>TOR Serine-Threonine Kinases--genetics<br/>Up-Regulation<br/>Young Adult